Blue Owl Capital Holdings LP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Blue Owl Capital Holdings LP lessened its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 118,238 shares of the biopharmaceutical company's stock after selling 45,000 shares during the period. Ultragenyx Pharmaceutical accounts for approximately 1.2% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 20th largest holding. Blue Owl Capital Holdings LP owned about 0.13% of Ultragenyx Pharmaceutical worth $4,974,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RARE. Vanguard Group Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after acquiring an additional 89,389 shares during the last quarter. Invesco Ltd. grew its stake in shares of Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock worth $71,509,000 after acquiring an additional 25,487 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Ultragenyx Pharmaceutical by 5.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock worth $68,487,000 after acquiring an additional 81,667 shares during the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock worth $49,375,000 after acquiring an additional 653,088 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Ultragenyx Pharmaceutical by 27.9% during the fourth quarter. Marshall Wace LLP now owns 1,051,573 shares of the biopharmaceutical company's stock worth $44,240,000 after acquiring an additional 229,561 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on RARE. HC Wainwright restated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Piper Sandler dropped their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $92.79.

Insider Activity

In other news, CEO Emil D. Kakkis sold 25,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $42.48, for a total value of $1,062,000.00. Following the sale, the chief executive officer now owns 2,158,985 shares in the company, valued at $91,713,682.80. This trade represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares in the company, valued at approximately $2,358,014.08. This trade represents a 5.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Trading Up 0.3 %

RARE traded up $0.12 on Tuesday, reaching $38.10. The stock had a trading volume of 154,003 shares, compared to its average volume of 814,635. Ultragenyx Pharmaceutical Inc. has a 12-month low of $29.59 and a 12-month high of $60.37. The business's 50-day moving average price is $37.79 and its two-hundred day moving average price is $43.54. The company has a market cap of $3.58 billion, a P/E ratio of -6.01 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.